Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
The Gillette logo will replace that of UnitedHealthcare, which became the Revolution’s first (and to date only) ...
The New England Revolution have unveiled jerseys with a new corporate name already familiar to Boston-area sports fans.
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
This was the stock's second consecutive day of losses.
Super Bowl 59 is officially in the books with the Philadelphia Eagles beating the Kansas City Chiefs. Here's a look at the ...
Overall, this will be the third Super Bowl that the Bay Area has hosted. Super Bowl XIX between the San Francisco 49ers and ...
EXCLUSIVE: The long-awaited film adaptation of Erik Larson’s bestselling book The Devil in the White City just got a shot of adrenaline, as sources tell Deadline that 20th Century has come on to ...
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine … ...
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback